April 2009
Volume 50, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2009
Identification of Protein Targets of Novel Neuroprotective Sulfhydryl Reducing Drugs
Author Affiliations & Notes
  • A. L. Kloosterboer
    Ophthalmology and Visual Sciences, University of Wisconsin Medical School, Madison, Wisconsin
  • J. R. Ribich
    Ophthalmology and Visual Sciences, University of Wisconsin Medical School, Madison, Wisconsin
  • L. A. Levin
    Ophthalmology and Visual Sciences, University of Wisconsin Medical School, Madison, Wisconsin
    Ophthalmology, University of Montreal, Montreal, Quebec, Canada
  • Footnotes
    Commercial Relationships  A.L. Kloosterboer, None; J.R. Ribich, None; L.A. Levin, Wisconsin Alumni Research Foundation, P.
  • Footnotes
    Support  NIH R21EY017970 and P30EY016665 and an unrestricted departmental grant from Research to Prevent Blindness, Inc.
Investigative Ophthalmology & Visual Science April 2009, Vol.50, 3190. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      A. L. Kloosterboer, J. R. Ribich, L. A. Levin; Identification of Protein Targets of Novel Neuroprotective Sulfhydryl Reducing Drugs. Invest. Ophthalmol. Vis. Sci. 2009;50(13):3190.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Previous work in our laboratory has shown elevated intracellular superoxide is a critical event in the death of retinal ganglion cells (RGCs) after axotomy. The sulfhydryl-reducing compounds tris(2-carboxyethyl) phosphine (TCEP) and bis(3-propionic acid methyl ester) phenylphosphine borane complex (PB1) rescue RGCs from apoptosis. We used a novel two-dimensional gel electophoresis method to detect changes in oxidation state of protein sulfyhydryls after treatment with PB1 in a transformed retinal ganglion cell-like cell line (RGC-5).

Methods: : Cultured RGC-5 cells were treated with 10 µM PB1 for 8 hours following which cellular and mitochondrial proteins were separated on a 4-20% polyacrylamide gradient gel. The lane was excised, reduced with 25 mM dithiothreitol, rinsed, and alkylated with 100 mM iodoacetamide. The excised slice was placed horizontally on a second gel, electrophoresed into the second dimension, and stained with Pierce® color silver stain or Sypro® Ruby.

Results: : Several proteins were found in consistent locations below the diagonal when prepared from control cells, but not cells treated with PB1, indicating that they contained disulfides that were reduced by PB1.

Conclusions: : A relatively small number of cellular and mitochondrial proteins are targets for the novel reducing agent PB1, and one or more may be critical for its activity as a neuroprotective agent.

Keywords: neuroprotection • protein purification and characterization • ganglion cells 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×